Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513175 · ClinicalTrials.gov registry record
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 44
- Enrollment target
NCT00513175: Completed study, sponsored by University of California, San Francisco.
NCT00513175 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00513175 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
Study Summary
The primary objective of this study is to examine transplant related mortality (TRM) at 100 days \<30%. A TRM of \>50% is considered unacceptable. This study also seeks a TRM at 12 months that is \<50%, engraftment \>90% (defined as donor cells \>80% at 6 months), and 1 year overall survival \>50%.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2001-10 |
| Est. Completion | 2007-11 |
What the finished NCT00513175 record still lists
NCT00513175 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00513175 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00513175 about?
NCT00513175 is a clinical study titled "Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia". The primary objective of this study is to examine transplant related mortality (TRM) at 100 days \<30%. A TRM of \>50% is considered unacceptable. This study also seeks a TRM at 12 months that is \<50%, engraftment \>90% (defined as donor cells \>80% at 6 months), and 1 year overall survival \>50%.
What is the current status of trial NCT00513175?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2001-10. Estimated completion is 2007-11.
Who is sponsoring clinical trial NCT00513175?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia